Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 8377 breast cancer patients

Research output: Contribution to journalArticle


Background: Urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) play essential roles in tumor invasion and metastasis. High levels of both uPA and PAT-1 are associated with poor prognosis in breast cancer patients. To confirm the prognostic value of uPA and PAI-1 in primary breast cancer, we reanalyzed individual patient data provided by members of the European Organization for Research and Treatment of Cancer-Receptor and Biomarker Group (EORTC-RBG). Methods: The study included 18 datasets involving 8377 breast cancer patients. During follow-up (median 79 months), 35% of the patients relapsed and 27% died. Levels of uPA and PAI-1 in tumor tissue extracts were determined by different immunoassays; values were ranked within each dataset and divided by the number of patients in that dataset to produce fractional ranks that could be compared directly across datasets. Associations of ranks of uPA and PAI-1 levels with relapse-free survival (RFS) and overall survival (OS) were analyzed by Cox multivariable regression analysis stratified by dataset, including the following traditional prognostic variables: age, menopausal status, lymph node status, tumor size, histologic grade, and steroid hormone-receptor status. All P values were two-sided. Results: Apart from lymph node status, high levels of uPA and PAI-1 were the strongest predictors of both poor RFS and poor OS in the analyses of all patients. Moreover, in both lymph node-positive and lymph nodenegative patients, higher uPA and PAI-1 values were independently associated with poor RFS and poor OS. For (untreated) lymph node-negative patients in particular, uPA and PAI-1 included together showed strong prognostic ability (all P<.001). Conclusions: This pooled analysis of the EORTC-RBG datasets confirmed the strong and independent prognostic value of uPA and PAI-1 in primary breast cancer. For patients with lymph node-negative breast cancer, uPA and PAI-1 measurements in primary tumors may be especially useful for designing individualized treatment strategies.


  • MP Look
  • WLJ van Putten
  • MJ Duffy
  • N Harbeck
  • IJ Christensen
  • C Thomssen
  • R Kates
  • F Spyratos
  • S Eppenberger-Castori
  • CGJF Sweep
  • K Ulm
  • JP Peyrat
  • PM Martin
  • H Magdelenat
  • N Brunner
  • C Duggan
  • BW Lisboa
  • V Quillien
  • A Daver
  • G Ricolleau
  • E Meijer-van Gelder
  • P Manders
  • WE Fiets
  • MA Blankenstein
  • P Broet
  • S Romain
  • G Daxenbichler
  • G Windbichler
  • T Cufer
  • S Borstnar
  • W Kueng
  • LVAM Beex
  • JGM Klijn
  • N O'Higgins
  • U Eppenberger
  • F Janicke
  • M Schmitt
  • JA Foekens
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
Original languageEnglish
Pages (from-to)116-128
JournalJournal of the National Cancer Institute
Issue number2
Publication statusPublished - 2002
Publication categoryResearch